key: cord-0991728-7buo4yxn
authors: Morris, Jerrine R.; Jaswa, Eleni Greenwood; Kaing, Amy; Hariton, Eduardo; Andrusier, Miriam; Aliaga, Katie E.; Davis, Maya Inez; Pasch, Lauri; Cedars, Marcelle I.; Huddleston, Heather G.
title: ANXIETY DURING THE COVID-19 PANDEMIC: PRELIMINARY FINDINGS FROM THE UCSF ASPIRE STUDY
date: 2021-09-30
journal: Fertility and Sterility
DOI: 10.1016/j.fertnstert.2021.07.028
sha: 655f25c529c5f93b9792e7ad609ebb4989153289
doc_id: 991728
cord_uid: 7buo4yxn

nan

vaginal blood (n¼13). On retesting the samples 3 to 20 days later, these results remained the same (positive test strip). The remaining 17 vaginal blood samples were from 4 women with ectopic pregnancies and from 13 non-pregnant women with vaginal bleeding. All 4 ectopic pregnancies had no AFP detected in the vaginal blood and only 1 out of 13 non-pregnant patient samples had AFP detected.

The ROMplus test strip correctly detected AFP in all samples tested containing fetal tissue (n¼13) resulting in a test sensitivity of 100%. ROMplus correctly identified the absence of AFP in 16 out of the 17 samples lacking fetal tissue, a 94% test specificity.

CONCLUSIONS: ROMplus has the potential to accurately and reliably detect the presence of AFP, and hence fetal tissue, in vaginal blood samples. This could be a vital non-invasive aid in ruling out an ectopic pregnancy at the bedside (currently off-label use). Furthermore, it could limit the amount of invasive testing and visits needed in cases of pregnancies of unknown location.

IMPACT STATEMENT: In light of the recent COVID-19 pandemic, a simple non-invasive bedside test to rule out an ectopic pregnancy is highly desired given its potential for reducing the number of visits, investigations performed, and personnel involved in the workup of a pregnancy of unknown location. Reference OBJECTIVE: To evaluate 17-a-hydroxyprogesterone (17-a-OHP) levels in post embryo transfer (ET) serum samples as a determinant of endometrial receptivity and pregnancy outcomes in IVF cycles MATERIALS AND METHODS: Prospective observational clinical study involving standard antagonist ovarian stimulation protocol in 716 fresh IVF cycles. Embryo transfer (n¼698) was done either on day3 (n¼223) or day5 (n¼475). Luteal phase was supported with micronized Progesterone injection. Serum (Sr.) levels of estradiol E2, Progesterone P and 17-a-OHP were measured by radioimmunoassay on d7 and d14 of ET. bhCG >50 mIU/ml on day14 ET was considered as positive indicator of pregnancy. Gestational sac with positive cardiac activity at 6 weeks confirmed clinical pregnancy. Data was compared between pregnant/non-pregnant and singleton/twin pregnancy. Statistical analysis was done using Graph-pad prism V software. Power of study >80% RESULTS: Overall Clinical Pregnancy rate was 36%. Pregnant women (n¼251) had significantly higher levels of Sr. 17-a-OHP on day7 ET (7.26 AE 0.43 vs. 2.63 AE 0.11 ng/ml, P<0.0001) and d14 ET (10.31 AE 0.72 vs. 2.41 AE 0.22 ng/ml, P<0.0001) compared to non-pregnant women (n¼447). Within the pregnant group, Sr. 17-a-OHP levels not only showed a marked rise from day7 to day14 but also significantly distinguished between singleton (n¼225) and twin (n¼26) pregnancies respectively (d7: 5.91 AE 0.39 vs. 11.15 AE 0.86 ng/ml, p<0.0001 and d14: 7.1AE0.24 vs. 12.82AE0.75 ng/ml, p<0.0001).

Clinical Pregnancy rate below and above the Day7 median value 3.6 ng/ml was 7.25% (24/331: only singletons) and 61.85% (227/367: 201 singletons, 26 twins) respectively. On Day7 Lower cut-off (25 th percentile) >2.5 ng/ml increased likelihood of pregnancy (ROC AUC : 96.43%, Sensitivity:92.56%, Specificity:75.89%) whereas upper cut-off (75 th percentile) >5.7 ng/ml enhanced the chances of a twin pregnancy. 17-a-OHP levels did not differ significantly whether embryos were transferred on day3 or day5. Although Sr. E2 levels on Day7 and day14 of ET were significantly higher in pregnant vs. non-pregnant group; they did not differ significantly between singleton vs. twin pregnancies. Sr. P levels on d7 and day14 of ET neither differed significantly between pregnant/non-pregnant nor between singleton/twin groups indicating that just luteal phase P support may not be enough for endometrial development.

CONCLUSIONS: Sr. 17-a-OHP is a strong indicator of enhanced endometrial response favorable for pregnancy. Day7 Sr. 17-a-OHP is also a robust EARLY predictive marker to distinguish between singleton and twin pregnancy much before visualization of an embryo-sac by ultrasonograhy is possible in IVF cycles.

IMPACT STATEMENT: First study to provide cutoff values for pregnancy and multiple gestation. This study introduces a novel, non-invasive serum biomarker 17-a-OHP, as an additional factor influencing endometrial receptivity; thus paving way for a better understanding of the process. Since 17-a-OHP robustly distinguishes singleton from twin pregnancy; it will help early management and avoid complications of multiple gestation.

SUPPORT: None OBJECTIVE: To describe the prevalence of anxiety symptoms in early pregnancy and identify predictors of early pregnancy anxiety during the COVID-19 pandemic.

MATERIALS AND METHODS: We assessed baseline moderate-to-severe anxiety symptoms after enrollment into the UCSF ASPIRE (Assessing the Safety of Pregnancy in the Coronavirus Pandemic) Prospective Cohort from May 2020 through February 2021. Pregnant persons <10 weeks' gestation completed questions regarding sociodemographic characteristics, obstetric/medical history, and pandemic-related experiences. Chi-square and multivariate hierarchical logistic regression analyses determined predictors of moderate or severe anxiety symptoms (GAD-7 R10). All analyses performed with Statistical Analysis Software (SASÒ) version 9.4. RESULTS: 4,303 persons completed the GAD-7 questionnaire. The mean age of this nationwide sample was 33 years and 25.7% of participants received care through a fertility clinic. 12.6% of pregnant persons reported moderate-to-severe anxiety symptoms. On univariate analysis, less than a college education (p<0.0001), pre-existing history of anxiety (p<0.0001), and history of prior miscarriage (p¼0.0143) were predictors of moderate-to-severe anxiety symptoms; care at a fertility center was protective (26.6% vs 25.7%, p¼ 0.0009). COVID-19 related stressors were strongly predictive of anxiety in pregnancy (p<0.0001). Race/ ethnicity and a prior history of live birth were not predictors of moderate-to-severe anxiety. In the hierarchical logistic regression model, pre-existing history of anxiety remained associated with anxiety during pregnancy. While education was no longer significant, there was a trend towards this being predictive.

Hierarchical Logistic regression predicting moderate to severe anxiety symptoms

Step 1

Step 2

Step 3

Step 1

Step 2

Step 3 CONCLUSIONS: Pre-existing history of anxiety and low maternal educational attainment likely exacerbated the contribution of stressors due to the COVID-19 pandemic on early pregnancy anxiety.

IMPACT STATEMENT: Socioeconomic disparities may exacerbate the contribution of pandemic-related stressors to early pregnancy anxiety risk. With limitations in prenatal care administration during the pandemic, continued emotional health support should remain an important focus for providers. OBJECTIVE: To characterize key parameters associated with the use of HP-hMG and PVS in a bridging study designed to evaluate the safety and efficacy of PVS after implementation of manufacturing enhancements.

MATERIALS AND METHODS: Prospective, open-label, single-arm, US trial conducted in 14 sites (NCT03565211). Women aged 18-34 years old with body mass index %38 kg/m2 and diagnosed with tubal, idiopathic, male factor, ovulatory dysfunction, or endometriosis-linked infertility underwent ovarian stimulation with highly purified human menotropin (HP-hMG) at a fixed dose of 225 IU/day, followed by adjustments according to individual response in a standardized long agonist protocol. Administration of the PVS (a silicone ring releasing 11 mg/day progesterone over 7 days) started the day after oocyte retrieval (OR), followed by fresh blastocyst transfer according to ASRM guidelines (2017), and continued for up to 10 weeks. The primary endpoint was the cumulative rate of any spontaneous abortion, defined as two positive b-hCG tests but followed by observation of any empty intrauterine gestational sac or one without a fetal heartbeat or absence of viable fetuses up to 12 weeks after OR.

RESULTS: Mean subject age was 30.8 years, BMI 26.5 kg/m2, AMH 2.9 ng/mL, and FSH 6.9 mIU/mL. 274 subjects initiated treatment with HP-hMG. The mean (SD) daily dose of HP-hMG was 258.7 IU (50.01) and mean duration was 10.1 days; 64.6% of subjects had %1 dose adjustment. The mean serum estradiol at end of stimulation was 2516 pg/mL. The mean (SD) oocytes, MII, and 2PN per subject were 11.0 (6.04), 8.2 (4.62), and 6.8 (3.93), respectively. This resulted in 4.1 (2.96) day 5 blastocysts and 2.8 (2.45) good quality day 5 blastocysts. Fresh embryo transfer after IVF/ICSI was performed in 243 (95.7%) of the 254 subjects treated with PVS. The primary trial objective was met, with a cumulative spontaneous abortion rate of 7.4% with upper bound of the 95% confidence interval (CI; 4.4%, 11.5%) below the predefined threshold of 15% set based upon the observed 10.0% rate (CI 7.6%, 12.8%) in the pivotal trial (Stadtmauer 2013) . Adverse events (AEs) occurring in R5% of the PVS treated population included biochemical abortion (9.8%), spontaneous abortion (7.1%), nausea (8.7%) and headache (5.1%). Mild and moderate ovarian hyperstimulation syndrome (OHSS) was noted in 3 and 4 subjects, respectively, with no cases of severe OHSS. Clinical pregnancy rates were 44.9% at 6 weeks post OR and 43.2% at 10 weeks post OR.

CONCLUSIONS: HP-hMG stimulation led to good blastocyst yields with a low incidence of OHSS. This trial established a safety bridge between PVS produced via enhanced manufacturing processes and the legacy PVS. Weekly administration of the PVS was well-tolerated with good pregnancy outcomes after stimulation with HP-hMG.

IMPACT STATEMENT: Given its demonstrated safety and efficacy, the recently FDA-approved PVS provides an important new option for luteal phase supplementation offering more convenient dosing than existing therapies.

O-19 10:45 AM Monday

This study aims to build a model incorporating personalized factors to assist patients in determining how many euploid embryos would convey a high likelihood of achieving a desired family size. MATERIALS AND METHODS: All single euploid embryo transfer (SEET) cycles from 2011-2020 were included in the study. Two models were built to predict the likelihood of 1 and 2 live births (LB) based on the number of SEET, the first including baseline characteristics and the second incorporating cycle characteristics. A multivariable random-intercept logistic model was used to compute the probability of LB after a single SEET (p(LB)), and a binomial probability model was used to compute the probability of at least 1 or 2 LB as a function of p(LB) and number of SEET. Variables were selected using backward selection based on the Bayesian Information Criterion. RESULTS: A total of 7434 SEET cycles were included, corresponding to 4586 patients